# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 46 results.
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Status: Not yet recruiting
Last Changed: Jul 08, 2020
First Received: Jun 09, 2020
Disease(s): Primary Central Nervous System Lymphoma, Recurrent Cancer
Intervention(s): Ibrutinib, Pembrolizumab, Rituximab
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Jan 18, 2016
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): R-IDARAM plus intrathecal chemotherapy
Locations: Navy General Hospital, Beijing, Beijing, China
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Jul 18, 2016
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): R-IDARAM plus intrathecal chemotherapy
Locations: Navy General Hospital, Beijing, Beijing, China
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
Status: Not yet recruiting
Last Changed: Jun 23, 2020
First Received: Jun 23, 2020
Disease(s): Primary CNS Lymphoma
Intervention(s): CD19CAR T-cells
Locations: University College London Hospital, London, United Kingdom
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Status: Recruiting
Last Changed: Jun 26, 2020
First Received: Apr 12, 2018
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
Locations: Aarhus University Hospital, Aarhus, Denmark
Oulu University Hospital, Oulu, Finland
Tampere University Hospital, Tampere, Finland
Bari IRCCS Istituto Tumori, Bari, Italy
ASST Spedali Civili di Brescia, Brescia, Italy
... and 22 other locations.
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Jul 21, 2020
First Received: Dec 10, 2018
Disease(s): Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Intervention(s): Ibrutinib, Nivolumab
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Status: Recruiting
Last Changed: Mar 09, 2020
First Received: Nov 17, 2017
Disease(s): Central Nervous System Lymphoma
Intervention(s): Resting State fMRI (rsfMRI), Auditory Attention and Executive Functions Test, Memory Test, Motor Speed Test, Self Reported Quality of Life Questionnaire
Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States
Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma
Status: Not yet recruiting
Last Changed: Oct 16, 2019
First Received: May 21, 2018
Disease(s): Central Nervous System Neoplasms, Primary
Intervention(s): Optune TTF device
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States
Lifespan Physician Group, Neurosurgery, Providence, Rhode Island, United States
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Jun 15, 2017
Disease(s): Lymphoma, Non-Hodgkin, Central Nervous System Neoplasms
Intervention(s): 18F-FDG, 18F-fluciclovine, standard MRI
Locations: Norwegian University of Science and Technology, Department of Circulation and Medical Imaging, Trondheim, Norway
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
Status: Recruiting
Last Changed: Jun 18, 2020
First Received: Jun 18, 2020
Disease(s): PCNSL, Secondary Central Nervous System Lymphoma
Intervention(s): ICP-022
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, Beijing, China
Capital Medical University Xuanwu Hospital, Beijing, Beijing, China
Guangdong General Hospital, Guangzhou, Guangdong, China
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
... and 1 other locations.